NASDAQ OMX : STOCKHOLM WELCOMES ENZYMATICA TO FIRST NORTH

Stockholm, June 15, 2015 - Nasdaq (Nasdaq: NDAQ) announces that the trading in Enzymatica AB's shares (short name: ENZY) commenced today on First North at Nasdaq Stockholm. Enzymatica, previously listed at Aktietorget, belongs to the Healthcare sector and is the 49th company to be admitted to trading on Nasdaq's Nordic markets* in 2015.

Enzymatica is a life science company whose business concept is to offer effective aid against some of the most common diseases where viruses or bacteria play a decisive role. Over a short period the company has developed a unique oral spray for common cold, ColdZyme®, and launched it on four markets. The product became the leading article for common cold at Swedish pharmacies during winter 2014-2015. The development program includes medical devices in upper respiratory infections and oral health, and veterinary products. The company is headquartered in Lund, Sweden. For more information, please visit www.enzymatica.com.

"We now have a unique product that keeps colds at bay and makes life easier for many users," said Fredrik Lindberg, CEO of Enzymatica. "In two years we have moved from zero to number one in Swedish pharmacies and thanks to the listing we have a stable foundation for our continued work to establish ColdZyme internationally. The increased knowledge and awareness of Enzymatica that the listing brings will help us in our continued development and expansion."

"We welcome Enzymatica to Nasdaq First North and to our family of companies," said Adam Kostyál, senior vice president and head of European listings at Nasdaq. "Nasdaq First North has over the years developed a strong healthcare segment and Enzymatica makes an exciting addition to that list."

Enzymatica AB has appointed Erik Penser Bankaktiebolag as Certified Adviser.

*Main markets and First North at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm.

About Nasdaq First North
Nasdaq First North is regulated as a multilateral trading facility, operated by the different exchanges within Nasdaq Nordic (Nasdaq First North Denmark is regulated as an alternative marketplace). It does not have the legal status as an EU-regulated market. Companies at Nasdaq First North are subject to the rules of Nasdaq First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market"

About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of over $9.5 trillion and more than 10,000 corporate clients. To learn more, visitnasdaq.com/ambition orbusiness.nasdaq.com .

Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland, Nasdaq Riga, Nasdaq Stockholm, Nasdaq Tallinn, Nasdaq Vilnius, Nasdaq Clearing and Nasdaq Broker Services are respectively brand names for the regulated markets of Nasdaq OMX Copenhagen A/S, Nasdaq OMX Helsinki Ltd., Nasdaq OMX Iceland hf., Nasdaq OMX Riga, AS, Nasdaq OMX Stockholm AB, Nasdaq OMX Tallinn AS, AB Nasdaq OMX Vilnius, Nasdaq OMX Clearing AB, Nasdaq OMX Broker Services AB. Nasdaq Nordic represents the common offering by Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm. Nasdaq Baltic represents the common offering by Nasdaq Tallinn, Nasdaq Riga and Nasdaq Vilnius.

Cautionary Note Regarding Forward-Looking Statements

The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Nasdaq and its products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These factors include, but are not limited to factors detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.